Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Table 3 Body weight-adjusted rivaroxaban dosing schedule for children aged birth–< 18 years, as evaluated in EINSTEIN-Jr^a

Body weight (kg)		Formulation	od dose	bid dose	tid dose	Total daily dose
Min	Max	Formulation	od dose	bid dose	tid dose	Total daily dose
2.6	< 3	Oral suspension			0.8 mg	2.4 mg
3	< 4	Oral suspension			0.9 mg	2.7 mg
4	< 5	Oral suspension			1.4 mg	4.2 mg
5	< 6	Oral suspension			1.6 mg	4.8 mg
6	< 7	Oral suspension			1.6 mg	4.8 mg
7	< 8	Oral suspension			1.8 mg	5.4 mg
8	< 9	Oral suspension			2.4 mg	7.2 mg
9	< 10	Oral suspension			2.8 mg	8.4 mg
10	< 12	Oral suspension			3.0 mg	9 mg
12	< 20	Oral suspension		5 mg		10 mg
20	< 30	Tablet/oral suspension		5 mg		10 mg
30	< 50	Tablet/oral suspension	15 mg			15 mg
≥ 50		Tablet/oral suspension	20 mg			20 mg

^aDosing regimen, including dosing frequency, will be adjusted if the child’s body weight changes during the study. ^†This dosing schedule may be subject to changes based on the results of the EINSTEIN-Jr phase III study; therefore, this dosing schedule cannot be used for the treatment of children with venous thrombosis outside the framework of the study
bid twice-daily, od once-daily, tid three-times-daily

ISSN: 1477-9560